Compare MobilEye Global Inc (MBLY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MobilEye Global Inc trades at $9.1 (market cap $7.54B), while State Street SPDR S&P Biotech ETF trades at $153.54. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| MBLY | XBI | |
|---|---|---|
Market Cap | $7.54B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $16.19 | $164.28 |
52-Week Low | $6.56 | $85.16 |
Enterprise Value | $6.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.95, down 2.93% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $392 million in 2025 despite revenue of $1.89 billion, reflecting negative profit margins. Recent news highlights its strategic shift toward launching a vertically integrated U.S. robotaxi service in 2027, generating significant media attention and analyst coverage.
The outlook hinges on execution of its robotaxi initiative, offering growth potential but carrying high execution risk. Analyst consensus is bullish with a $10.71 price target, yet profitability challenges and competitive pressures pose substantial risks. Investors should weigh the long-term transformation against current financial weakness.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
